{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:14:10Z","timestamp":1794899650618,"version":"4.9.1"},"reference-count":44,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The tumor microenvironments (TME) of diffuse large B-cell lymphoma (DLBCL) subgroups have remained poorly characterized. Here, we dissected the composition and spatial organization of the TME in germinal center B-cell (GCB), activated B-cell (ABC), and testicular (T-) DLBCL using gene expression profiling and multiplex immunohistochemistry. We found that high proportions of M2-like tumor-associated macrophages (TAM) and cytotoxic tumor-infiltrating T cells (TIL) were characteristic of ABC DLBCL TME. Furthermore, high CD8+ TIL content translated to favorable outcomes. In contrast, GCB DLBCL TME was enriched in CD4+ TIL, regulatory TIL, and a higher M1-like: M2-like TAM ratio, and high proportions of TAM and Granzyme B+ cells associated with worse survival. TIL and TAM interacted more frequently with M2-like TAM and cytotoxic TIL in the ABC DLBCL in contrast to GCB subtype, where the interactions were more abundant with other TIL and CD4+ TIL. In T-DLBCL, TME resembled that of ABC DLBCL with a higher proportion of M2-like TAM and cytotoxic cells, except that checkpoint-positive TIL were less prominent compared to DLBCL NOS. Cytotoxic TIL also interacted more with TIL and TAM. A large number of CD163+ TAM interactions with distinct TIL translated to unfavorable survival both in GCB DLBCL and T-DLBCL, whereas a high number of interactions between TIL and TAM, CD4+ TIL and TAM, and CD4+ TIL and other TIL were associated with favorable outcomes only in T-DLBCL. Together, our data demonstrate biologically and clinically relevant differences in the composition of and cellular interactions in the TME between various DLBCL entities.<\/jats:p>","DOI":"10.3324\/haematol.2024.286267","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T03:41:06Z","timestamp":1733974866000},"page":"1339-1350","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas"],"prefix":"10.3324","volume":"110","author":[{"given":"Matias","family":"Autio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjukka","family":"Pollari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Karjalainen-Lindsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit M\u00e9szaros","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Holte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teijo","family":"Pellinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi-Katri","family":"Leivonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"75677","doi-asserted-by":"crossref","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014; 14(8):517-534.","DOI":"10.1038\/nrc3774"},{"key":"75678","doi-asserted-by":"crossref","unstructured":"Nicholas NS, Apollonio B, Ramsay AG. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. Biochim Biophys Acta. 2016; 1863(3):471-482.","DOI":"10.1016\/j.bbamcr.2015.11.003"},{"key":"75679","doi-asserted-by":"crossref","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14(10):1014-1022.","DOI":"10.1038\/ni.2703"},{"key":"75680","doi-asserted-by":"crossref","unstructured":"Kotlov N, Bagaev A, Revuelta MV. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021; 11(6):1468-1489.","DOI":"10.1158\/2159-8290.CD-20-0839"},{"key":"75681","doi-asserted-by":"crossref","unstructured":"Steen CB, Luca BA, Esfahani MS. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 2021; 39(10):1422-1437.e10.","DOI":"10.1016\/j.ccell.2021.08.011"},{"key":"75682","doi-asserted-by":"crossref","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12(4):298-306.","DOI":"10.1038\/nrc3245"},{"key":"75683","doi-asserted-by":"crossref","unstructured":"Cai QC, Liao H, Lin SX. High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol. 2012; 29(4):2317-2322.","DOI":"10.1007\/s12032-011-0123-6"},{"key":"75684","doi-asserted-by":"crossref","unstructured":"Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemoimmunotherapy. Am J Hematol. 2013; 88(4):273-276.","DOI":"10.1002\/ajh.23398"},{"key":"75685","doi-asserted-by":"crossref","unstructured":"Riihij\u00e4rvi S, Fiskvik I, Taskinen M. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2015; 100(2):238-245.","DOI":"10.3324\/haematol.2014.113472"},{"key":"75686","doi-asserted-by":"crossref","unstructured":"Xu-Monette ZY, Xiao M, Au Q. Immune profiling and quantitative analysis decipher the clinical role of immunecheckpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res. 2019; 7(4):644-657.","DOI":"10.1158\/2326-6066.CIR-18-0439"},{"key":"75687","doi-asserted-by":"crossref","unstructured":"Autio M, Leivonen SK, Br\u00fcck O. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2021; 106(3):718-729.","DOI":"10.3324\/haematol.2019.243626"},{"key":"75688","doi-asserted-by":"crossref","unstructured":"Autio M, Leivonen SK, Br\u00fcck O, Karjalainen-Lindsberg ML, Pellinen T, Lepp\u00e4 S. Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment. Clin Cancer Res. 2022; 28(4):781-792.","DOI":"10.1158\/1078-0432.CCR-21-3140"},{"key":"75689","doi-asserted-by":"crossref","unstructured":"Colombo AR, Hav M, Singh M. Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma. Blood Adv. 2022; 6(16):4675-4690.","DOI":"10.1182\/bloodadvances.2022007493"},{"key":"75690","doi-asserted-by":"crossref","unstructured":"Wright KT, Weirather JL, Jiang S. Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging. Blood Adv. 2023; 7(16):4633-4646.","DOI":"10.1182\/bloodadvances.2023009813"},{"key":"75691","doi-asserted-by":"crossref","unstructured":"Ansell SM, Minnema MC, Johnson P. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019; 37(6):481-489.","DOI":"10.1200\/JCO.18.00766"},{"key":"75692","doi-asserted-by":"crossref","unstructured":"Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.","DOI":"10.1038\/35000501"},{"key":"75693","doi-asserted-by":"crossref","unstructured":"Fu K, Weisenburger DD, Choi WW. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol. 2008; 26(28):4587-4594.","DOI":"10.1200\/JCO.2007.15.9277"},{"key":"75694","doi-asserted-by":"crossref","unstructured":"Lenz G, Wright G, Dave SS. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-2323.","DOI":"10.1056\/NEJMoa0802885"},{"key":"75695","doi-asserted-by":"crossref","unstructured":"Bea S, Zettl A, Wright G. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005; 106(9):3183-3190.","DOI":"10.1182\/blood-2005-04-1399"},{"key":"75696","doi-asserted-by":"crossref","unstructured":"Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma. Blood. 2018; 131(21):2307-2319.","DOI":"10.1182\/blood-2017-11-764332"},{"key":"75697","doi-asserted-by":"crossref","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-1874.","DOI":"10.1084\/jem.194.12.1861"},{"key":"75698","doi-asserted-by":"crossref","unstructured":"Morin RD, Johnson NA, Severson TM. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010; 42(2):181-185.","DOI":"10.1038\/ng.518"},{"key":"75699","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Chan WC. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-1947.","DOI":"10.1056\/NEJMe020050"},{"key":"75700","doi-asserted-by":"crossref","unstructured":"Schmitz R, Wright GW, Huang DW. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018; 378(15):1396-1407.","DOI":"10.1056\/NEJMoa1801445"},{"key":"75701","doi-asserted-by":"crossref","unstructured":"Chapuy B, Stewart C, Dunford AJ. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690.","DOI":"10.1038\/s41591-018-0016-8"},{"key":"75702","doi-asserted-by":"crossref","unstructured":"Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014; 123(4):486-493.","DOI":"10.1182\/blood-2013-10-530659"},{"key":"75703","doi-asserted-by":"crossref","unstructured":"Deng L, Xu-Monette ZY, Loghavi S. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016; 30(2):361-372.","DOI":"10.1038\/leu.2015.237"},{"key":"75704","doi-asserted-by":"crossref","unstructured":"Leivonen SK, Pollari M, Bruck O. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019; 104(2):338-346.","DOI":"10.3324\/haematol.2018.200105"},{"key":"75705","doi-asserted-by":"crossref","unstructured":"Holte H, Leppa S, Bjorkholm M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/ follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013; 24(5):1385-1392.","DOI":"10.1093\/annonc\/mds621"},{"key":"75706","doi-asserted-by":"crossref","unstructured":"Lepp\u00e4 S, J\u00f8rgensen J, Tierens A. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020; 4(9):1906-1915.","DOI":"10.1182\/bloodadvances.2020001518"},{"key":"75707","doi-asserted-by":"crossref","unstructured":"Meriranta L, Pasanen A, Alkodsi A, Haukka J, Karjalainen-Lindsberg ML, Lepp\u00e4 S. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. Blood Adv. 2020; 4(15):3742-3753.","DOI":"10.1182\/bloodadvances.2020001727"},{"key":"75708","doi-asserted-by":"crossref","unstructured":"Reddy A, Zhang J, Davis NS. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017; 171(2):481-494.","DOI":"10.1016\/j.cell.2017.09.027"},{"key":"75709","doi-asserted-by":"crossref","unstructured":"Scott DW, Wright GW, Williams PM. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014; 123(8):1214-1217.","DOI":"10.1182\/blood-2013-11-536433"},{"key":"75710","doi-asserted-by":"crossref","unstructured":"Isaksen KT, Beiske K, Smeland EB. The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma. EJHaem. 2021; 2(1):104-108.","DOI":"10.1002\/jha2.109"},{"key":"75711","doi-asserted-by":"crossref","unstructured":"Pollari M, Pellinen T, Karjalainen-Lindsberg ML, Kellokumpu-Lehtinen PL, Leivonen SK, Lepp\u00e4 S. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. Eur J Haematol. 2020; 105(6):712-721.","DOI":"10.1111\/ejh.13484"},{"key":"75712","doi-asserted-by":"crossref","unstructured":"Berg S, Kutra D, Kroeger T. ilastik: interactive machine learning for (bio)image analysis. Nat Methods. 2019; 16(12):1226-1232.","DOI":"10.1038\/s41592-019-0582-9"},{"key":"75713","doi-asserted-by":"crossref","unstructured":"Carpenter AE, Jones TR, Lamprecht MR. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006; 7(10)","DOI":"10.1186\/gb-2006-7-10-r100"},{"key":"75714","doi-asserted-by":"crossref","unstructured":"Br\u00fcck O, Lee MH, Turkki R. Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. Mod Pathol. 2021; 34(12):2229-2241.","DOI":"10.1038\/s41379-021-00864-0"},{"key":"75715","doi-asserted-by":"crossref","unstructured":"Liarski VM, Sibley A, van Panhuys N. Quantifying in situ adaptive immune cell cognate interactions in humans. Nat Immunol. 2019; 20(4):503-513.","DOI":"10.1038\/s41590-019-0315-3"},{"key":"75716","doi-asserted-by":"crossref","unstructured":"Pollari M, Bruck O, Pellinen T. PD-L1(+) tumor-associated macrophages and PD-1(+) tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica. 2018; 103(11):1908-1914.","DOI":"10.3324\/haematol.2018.197194"},{"key":"75717","doi-asserted-by":"crossref","unstructured":"Dufva O, P\u00f6l\u00f6nen P, Br\u00fcck O. Immunogenomic landscape of hematological malignancies. Cancer Cell. 2020; 38(3):380-399.","DOI":"10.1016\/j.ccell.2020.06.002"},{"key":"75718","doi-asserted-by":"crossref","unstructured":"Fangazio M, Ladewig E, Gomez K. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2021; 118(22):e2104504118.","DOI":"10.1073\/pnas.2104504118"},{"key":"75719","doi-asserted-by":"crossref","unstructured":"McCord R, Bolen CR, Koeppen H. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019; 3(4):531-540.","DOI":"10.1182\/bloodadvances.2018020602"},{"key":"75720","doi-asserted-by":"crossref","unstructured":"Li L, Sun R, Miao Y. PD-1\/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019; 32(6):741-754.","DOI":"10.1038\/s41379-018-0193-5"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11869\/77883","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11869\/78416","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11869\/77883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:51Z","timestamp":1794046071000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286267","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}